Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients

NCT05923905 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Sporadic and Familial Amyotrophic Lateral Sclerosis

Interventions

DRUG: FB1006
DRUG: Placebo

Sponsor

Peking University Third Hospital